Kanabo Group Plc

KNB

GB00BYQCS703

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.7 ^GBX	0.00%		+2.10%	-39.29%

Mar. 28	Kanabo shares soar after company announces UK mental health service	AN
Mar. 28	Kanabo Group plc Announces Expansion of Treat It Clinic to Offer Mental Health Treatments	CI

Kanabo Group Plc Reports Earnings Results for the Half Year Ended June 30, 2023

September 29, 2023 at 02:00 am EDT

Kanabo Group Plc reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was GBP 0.449 million compared to GBP 0.239 million a year ago. Net loss was GBP 1.56 million compared to GBP 3.78 million a year ago.

Basic loss per share from continuing operations was GBP 0.0035.

Latest news about Kanabo Group Plc

Kanabo shares soar after company announces UK mental health service	Mar. 28	AN
Kanabo Group plc Announces Expansion of Treat It Clinic to Offer Mental Health Treatments	Mar. 28	CI
Kanabo shares higher as Germany reclassifies medical cannabis	Mar. 25	AN
Kanabo subsidiary receives EUR200,000 for Spanish project	Mar. 18	AN
Kanabo Group Partners with City Dock Pharmacy for Walk-in Pain Clinic in London; Stock Rises	Jan. 15	MT
Kanabo shares up on deal to launch walk-in pain clinic in London	Jan. 15	AN
Kanabo Group Plc Announces Partnership with City Dock Pharmacy to Launch A Walk-In Pain Clinic	Jan. 15	CI
Technology Minerals, Beeks Financial hail deal wins	Nov. 14	AN
Kanabo Secures Contract Extension for Online Consultation Services in UK	Nov. 14	MT
Kanabo Group plc Announces Contract Extension with Major UK Retailer	Nov. 14	CI
EARNINGS AND TRADING: Kanabo inks CBD deal, Taseko boosts production	Nov. 02	AN
Kanabo Group plc Announces Partnership with BRITISH CANNABIS	Nov. 02	CI
FTSE 100 Closes Up, Capping off a Positive Quarter	23-09-29	DJ
EARNINGS: Beacon Energy and Kefi Gold & Copper losses widen	23-09-29	AN
Earnings Flash (KNB.L) KANABO GROUP Reports H1 Revenue GBP449,000	23-09-29	MT
Earnings Flash (KNB.L) KANABO GROUP Reports H1 Loss GBX-0.35	23-09-29	MT
Kanabo Group Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Kanabo subsidiary inks deal with Taima Growth for cannabis in Madrid	23-07-17	AN
On The Beach rejigs board, names new CEO and CFO	23-06-30	AN
Cornerstone FS revenue doubles, loss widens	23-05-16	AN
FTSE 100 Closes Down Dragged by Property Stocks; IAG Shines	23-05-09	DJ
Kanabo Completes GBP2.5 Million Equity Raise	23-05-09	MT
Kanabo raises GBP2.5 million in fundraise, hires Ian Mattioli as chair	23-05-09	AN
UK Home Builders Drop as House Prices Fall in April	23-05-09	DJ
BOE Could Begin to Cautiously Cut Rates in 4Q	23-05-09	DJ

Chart Kanabo Group Plc

Duration

Period

More charts

Company Profile

Kanabo Group plc is a United Kingdom-based patient-focused provider of digital health services and specialist medicines, including medicinal cannabis. The Companyâs principal activities are the distribution and development of cannabis derived medical and wellness products. The Company is focused on the distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. It has conducted research and development (R&D) in order to develop cannabis extract formulas, medical-grade vaporizers and various non-smoking consumption solutions. Its clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The Company operates through two segments: Primary case and Secondary case. Primary case segment is involved in the telepharma services provided by GPS. Secondary case segment is involved in the distribution and development of cannabis-derived medical and wellness products.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KANABO GROUP PLC	-39.29%	13.39M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B